Targeted pill shows promise for rare cancers with specific gene flaw
NCT ID NCT02073994
First seen Mar 11, 2026 · Last updated Apr 30, 2026 · Updated 6 times
Summary
This early-phase study tested an oral drug called AG-120 in 174 people with advanced solid tumors (including bile duct cancer, cartilage cancer, and brain tumors) that have a specific IDH1 gene mutation. The goal was to find a safe dose and see how the drug works in the body. Participants took the drug until their disease worsened or side effects became too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Study site
Scottsdale, Arizona, 85258, United States
-
Study site
Los Angeles, California, 90095, United States
-
Study site
Aurora, Colorado, 80045, United States
-
Study site
Miami, Florida, 33136, United States
-
Study site
Baltimore, Maryland, 21218, United States
-
Study site
Boston, Massachusetts, 02215, United States
-
Study site
New York, New York, 10065, United States
-
Study site
Nashville, Tennessee, 37203, United States
-
Study site
Dallas, Texas, 75390, United States
-
Study site
Houston, Texas, 77030, United States
-
Study site
San Antonio, Texas, 78229, United States
-
Study site
Villejuif, 94800, France
Conditions
Explore the condition pages connected to this study.